Mouse models of prostate cancer: Picking the best model for the question

Magdalena M. Grabowska, David Degraff, Xiuping Yu, Ren Jie Jin, Zhenbang Chen, Alexander D. Borowsky, Robert J. Matusik

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no genetically engineered mouse (GEM) models of prostate cancer (PCa). Today, a PubMed search for "prostate cancer mouse model" yields 3,200 publications and this list continues to grow. The first generation of GEM utilized the newly discovered and characterized probasin promoter driving viral oncogenes such as Simian virus 40 large T antigen to yield the LADY and TRAMP models. As the PCa research field has matured, the second generation of models has incorporated the single and multiple molecular changes observed in human disease, such as loss of PTEN and overexpression of Myc. Application of these models has revealed that mice are particularly resistant to developing invasive PCa, and once they achieve invasive disease, the PCa rarely resembles human disease. Nevertheless, these models and their application have provided vital information on human PCa progression. The aim of this review is to provide a brief primer on mouse and human prostate histology and pathology, provide descriptions of mouse models, as well as attempt to answer the age old question: Which GEM model of PCa is the best for my research question?

Original languageEnglish (US)
Pages (from-to)377-397
Number of pages21
JournalCancer and Metastasis Reviews
Volume33
Issue number2-3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Prostatic Neoplasms
Prostate
Simian virus 40
Viral Tumor Antigens
National Institutes of Health (U.S.)
Oncogenes
Research
PubMed
Publications
Histology
Pathology
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Grabowska, M. M., Degraff, D., Yu, X., Jin, R. J., Chen, Z., Borowsky, A. D., & Matusik, R. J. (2014). Mouse models of prostate cancer: Picking the best model for the question. Cancer and Metastasis Reviews, 33(2-3), 377-397. https://doi.org/10.1007/s10555-013-9487-8
Grabowska, Magdalena M. ; Degraff, David ; Yu, Xiuping ; Jin, Ren Jie ; Chen, Zhenbang ; Borowsky, Alexander D. ; Matusik, Robert J. / Mouse models of prostate cancer : Picking the best model for the question. In: Cancer and Metastasis Reviews. 2014 ; Vol. 33, No. 2-3. pp. 377-397.
@article{44395e6e04f84fa0a46281d798a0a070,
title = "Mouse models of prostate cancer: Picking the best model for the question",
abstract = "When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no genetically engineered mouse (GEM) models of prostate cancer (PCa). Today, a PubMed search for {"}prostate cancer mouse model{"} yields 3,200 publications and this list continues to grow. The first generation of GEM utilized the newly discovered and characterized probasin promoter driving viral oncogenes such as Simian virus 40 large T antigen to yield the LADY and TRAMP models. As the PCa research field has matured, the second generation of models has incorporated the single and multiple molecular changes observed in human disease, such as loss of PTEN and overexpression of Myc. Application of these models has revealed that mice are particularly resistant to developing invasive PCa, and once they achieve invasive disease, the PCa rarely resembles human disease. Nevertheless, these models and their application have provided vital information on human PCa progression. The aim of this review is to provide a brief primer on mouse and human prostate histology and pathology, provide descriptions of mouse models, as well as attempt to answer the age old question: Which GEM model of PCa is the best for my research question?",
author = "Grabowska, {Magdalena M.} and David Degraff and Xiuping Yu and Jin, {Ren Jie} and Zhenbang Chen and Borowsky, {Alexander D.} and Matusik, {Robert J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10555-013-9487-8",
language = "English (US)",
volume = "33",
pages = "377--397",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "2-3",

}

Grabowska, MM, Degraff, D, Yu, X, Jin, RJ, Chen, Z, Borowsky, AD & Matusik, RJ 2014, 'Mouse models of prostate cancer: Picking the best model for the question', Cancer and Metastasis Reviews, vol. 33, no. 2-3, pp. 377-397. https://doi.org/10.1007/s10555-013-9487-8

Mouse models of prostate cancer : Picking the best model for the question. / Grabowska, Magdalena M.; Degraff, David; Yu, Xiuping; Jin, Ren Jie; Chen, Zhenbang; Borowsky, Alexander D.; Matusik, Robert J.

In: Cancer and Metastasis Reviews, Vol. 33, No. 2-3, 01.01.2014, p. 377-397.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Mouse models of prostate cancer

T2 - Picking the best model for the question

AU - Grabowska, Magdalena M.

AU - Degraff, David

AU - Yu, Xiuping

AU - Jin, Ren Jie

AU - Chen, Zhenbang

AU - Borowsky, Alexander D.

AU - Matusik, Robert J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no genetically engineered mouse (GEM) models of prostate cancer (PCa). Today, a PubMed search for "prostate cancer mouse model" yields 3,200 publications and this list continues to grow. The first generation of GEM utilized the newly discovered and characterized probasin promoter driving viral oncogenes such as Simian virus 40 large T antigen to yield the LADY and TRAMP models. As the PCa research field has matured, the second generation of models has incorporated the single and multiple molecular changes observed in human disease, such as loss of PTEN and overexpression of Myc. Application of these models has revealed that mice are particularly resistant to developing invasive PCa, and once they achieve invasive disease, the PCa rarely resembles human disease. Nevertheless, these models and their application have provided vital information on human PCa progression. The aim of this review is to provide a brief primer on mouse and human prostate histology and pathology, provide descriptions of mouse models, as well as attempt to answer the age old question: Which GEM model of PCa is the best for my research question?

AB - When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no genetically engineered mouse (GEM) models of prostate cancer (PCa). Today, a PubMed search for "prostate cancer mouse model" yields 3,200 publications and this list continues to grow. The first generation of GEM utilized the newly discovered and characterized probasin promoter driving viral oncogenes such as Simian virus 40 large T antigen to yield the LADY and TRAMP models. As the PCa research field has matured, the second generation of models has incorporated the single and multiple molecular changes observed in human disease, such as loss of PTEN and overexpression of Myc. Application of these models has revealed that mice are particularly resistant to developing invasive PCa, and once they achieve invasive disease, the PCa rarely resembles human disease. Nevertheless, these models and their application have provided vital information on human PCa progression. The aim of this review is to provide a brief primer on mouse and human prostate histology and pathology, provide descriptions of mouse models, as well as attempt to answer the age old question: Which GEM model of PCa is the best for my research question?

UR - http://www.scopus.com/inward/record.url?scp=84905088552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905088552&partnerID=8YFLogxK

U2 - 10.1007/s10555-013-9487-8

DO - 10.1007/s10555-013-9487-8

M3 - Review article

C2 - 24452759

AN - SCOPUS:84905088552

VL - 33

SP - 377

EP - 397

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 2-3

ER -